Daniel Castellano

No patient should receive more treatment than they need - or less than they deserve. But: The goal is not to avoid surgery at all costs. For *selected* patients with recurrent low-grade IR NMIBC, intravesical neoadjuvant chemotherapy may offer a real alternative to repeated TURBT - preserving the bladder, reducing surgical burden, and improving quality of life. #BladderCancer @GustavoVillold4 @joanfundi @rodriguezfaba @fcandiagaston #AUA26

New in our partnership with @DGlaucomflecken: the KEYNOTE-905 trial evaluated enfortumab vedotin plus pembrolizumab as perioperative therapy in patients with muscle-invasive bladder cancer who were ineligible to receive cisplatin. Read the full study for free: nej.md/DrG40

AR for prostate. ER for breast. PPARγ for bladder? ➡️ FX-909, first-in-class oral PPARγ inverse agonist ➡️ Confirmed PRs in PPARγ-high UC, post EV/pembro and ICI ➡️ Companion IHC biomarker (TPS ≥60%) built in from phase 1 💡It was an oral at GU ASCO by the @MattGalsky and now Nature Medicine pub, congrats! Look forward to see future work and combination. 🧬 📄 bit.ly/4tWHAlA #BladderCancer #UrothelialCA #GUonc

🎯🔥⚽️the most funky, friendly, fashioned social event is coming again!! 💪💪 @ASCO @ASCOPres 🚀 The World #ASCO26 football Cup! @DrChoueiri @FAndreMD 📆 Saturday May 30th (6.00-10.00PM) Place:SOFIVE-CHITOWN Soccer Center(2343 S Throop St,Chicago, IL) Registration is open Contact: cdanicas@gmail.com 🙌🙌Brasil, Argentina, Colombia,Peru and USA are confirmed🏃‍♂️🏃‍♂️ 😎 Don't miss it and sign up!🔥 With a rock stars @DrChoueiri !! @OncoAlert @aaoncoclinica @SoaresAndrey @myESMO @raymanneh @GuardConsortium @DrFelixGuerrero

🎯🔥⚽️the most funky, friendly, fashioned social event is coming again!! 💪💪 @ASCO @ASCOPres 🚀 The World #ASCO26 football Cup! @DrChoueiri @FAndreMD 📆 Saturday May 30th (6.00-10.00PM) Registration is open Contact: cdanicas@gmail.com 🙌🙌Brasil, Argentina, Colombia,Peru and USA are confirmed🏃‍♂️🏃‍♂️ The latest versions were a lot of fun. 😎 Don't miss it and sign up!🔥 With a rock stars @DrChoueiri !! @OncoAlert @aaoncoclinica @SoaresAndrey @myESMO @raymanneh @GuardConsortium @DrFelixGuerrero

Deprioritization of zelenectide pevedotin (nectin-4/MMAE peptide) has occurred in bladder cancer prior to the randomised phase 3 starting (Duravelo-2: 1st line ZP/pembro vs gem/platinum control). The dose finding phase 2 seemed successful (see below) but regulatory feedback questioned the study design - probably the control arm of platinum chemotherapy. EVP is widely established standard of care making it hard to get combos with similar MOA approved. But Randomised phase 3s with EVP as the control (FORAGER-2: Vepugratinib (FGFR3)) are ongoing. @y_loriot @OncoAlert

Internationally recognized experts come together to deliver a truly high-level scientific experience in bladder, kidney, and prostate cancer 📍 San Sebastián, Spain 📅 June 25–26, 2026 gucancersummit.com

Incredible #APCC26 @APCCC_Lugano meeting - Lugano 🇨🇭 Experts in advanced PCa providing comprehensive, contemporary updates from HR BCR all the way through >2L mCRPC Congrats @Silke_Gillessen @AOmlin on another great meeting! All the content @urotoday - urotoday.com/conference-hig…

📊 Insight clínico En carcinoma renal, el reto ya no es solo la 1ª línea, sino qué hacer después. 🔍 Alta variabilidad en secuencias y falta de evidencia comparativa. La vida real será clave para responder. #GUARDConsortium #RenalCancer @DrFelixGuerrero @cdanicas @dralvaropinto @drenriquegrande @fcounago @docjavip @BerUrologia @DrJaVallejo @Maroto5Pablo @nachoduranm @RodriguezAntona @AnaPlatabello1

@davisa20 @alitimumab @ASCO @PSG_inside I attest that @davisa20 are adding significant joy/quality of life to all @ASCO meetings by making sure Live @ChampionsLeague games are broadcasted ! Viva Mandy! @FAndreMD @cdanicas @OncoAlert #beatfabrice #ASCO26

📣Applications to the 2026 ESMO preceptorship on prostate cancer are open until 22 June‼️ Join us in Zurich 16-17 Sept. Complementary registration and accommodation are provided. @myESMO esmo.org/meeting-calend…

🚨SAVE THE DATE! 9th June @H12Octubre 👩‍🏫MASTERCLASS IN BLADDER CANCER 2026, register here: t.ly/oq7v8 🔝Program with TOP speakers @cdanicas @PazAresLab @docjavip @MartaDueas4 @AlvarezMa89031 @DominguezEscrig @RodriguezFaba @evanguelosx @MarioHArroyo @elenasefer @FaltasLab @LAUrology_NL @dr_flozano @A_Carrion_Puig @josedsh @dralvaropinto @cgdelcanizo @g_develasco @mjuanfi81 @drenriquegrande @giannatempopatr @nachoduranm @tactics_md @H12Octubre @InfoAeu @ResidentesAEU @Urologia12

The diagnostic value of mpMRI and PSMA-targeted PET/CT in radiorecurrent prostate cancer: a narrative review frontiersin.org/journals/oncol… Review evaluates mpMRI and PSMA-targeted PET/CT for restaging radiorecurrent #ProstateCancer after radiotherapy☢️ Across 10 studies, mpMRI showed moderate-to-high specificity but variable sensitivity, often underestimating multifocal disease. PSMA-targeted PET/CT demonstrated high sensitivity for intraprostatic recurrence and superior detection of nodal and distant metastases. Combined imaging achieved the highest diagnostic confidence, supporting improved patient selection for salvage therapy, although histologic confirmation remains essential before treatment. Umberto Merani @AMarquis_MD @GMarra_MD @paolo_gontero @oderdam @OncoAlert 🚨 @Silke_Gillessen @AOmlin @weoncologists

📘 Nuevo recurso @CANVES_ES  La hematuria es uno de los principales signos de alerta en cáncer de vejiga. Os compartimos un material claro para pacientes y entorno. 🔗 Descárgalo aquí: canves.us8.list-manage.com/track/click?u=… #CancerDeVejiga #Prevención @DrFelixGuerrero @cdanicas @dralvaropinto @drenriquegrande @fcounago @docjavip @BerUrologia @DrJaVallejo @Maroto5Pablo @nachoduranm @RodriguezAntona @AnaPlatabello1

Local Salvage Therapy Alone for Local Recurrence of Prostate Cancer After Radiotherapy: A Systematic Review and Meta-Analysis jamanetwork.com/journals/jamao… Local salvage therapies for radiorecurrent prostate cancer show reasonable outcomes in selected patients wishing to avoid androgen deprivation therapy. Across 31 studies (4525 patients), 2- and 5-year ADT-free survival were 76.8% and 55.2%, while metastasis-free survival reached 90.4% and 75.2%. Severe adverse events varied by modality (2–14%). Despite selection bias and limited randomized data, these approaches☢️offer a viable alternative with acceptable toxicity and meaningful disease control. #ProstateCancer @miszczyk_marcin @AmarUKishan @ArjunSNathan @BarbaraJereczek @DrShariat @dr_rajwa @GiulioFrancoli1 @GMarra_MD @paolo_gontero @PetePocharapong @OncoAlert 🚨 @Silke_Gillessen @AOmlin @weoncologists

📢 Ampliamos plazo hasta el 10 de mayo Tu opinión es clave para entender cómo se forma la nueva generación en tumores GU. 📝 Participa en la encuesta de #GUARDConsortium y ayúdanos a diseñar mejores programas formativos. 👉 form.jotform.com/260831801425047 @DrFelixGuerrero @cdanicas @dralvaropinto @drenriquegrande @fcounago @docjavip @BerUrologia @DrJaVallejo @Maroto5Pablo @nachoduranm @RodriguezAntona @AnaPlatabello1

Priority Editorial! When Patients Refuse Radical Cystectomy: Integrating Trimodality Therapy in the Perioperative ICI/ADC Era by Martino Pedrani et al Read the full article: buff.ly/n6uKXj0 We thank the authors for their insight. @PedraniMartino @DeGiorgiAlberto @AndreaGallina5 @UrsulaVogl @ZilliThomas @uroweb @mroupret @GPloussard @jteoh_hk @Ric_Campi @CaPsurvivorship @LauraMarandino @RenuEapen @Ecastromarcos @OncoAlert @Sciencedirect

So if we do not see a benefit from Abi in mHSPC pts older than 75yo, I presume we also won’t see a benefit in pts locally advanced M0 HSPC trials. The median age in STAMPEDE M0 was 67. What was it in Enzarad/GU009 @DrPaulNguyen? InThunder trial, median age is 77 yo 🫣! ⁦

@brookmans76 Congrats Sabine! Sounds awesome!👏

I am very happy to share that I am starting a new role today, as VP Global Head of Clinical Development at Curium - a deliberate move to re-focus on #ProstateCancer (and beyond) and to expand into #RadioligandTherapy (#RLT) and precision Imaging. At Curium, I’ll be leading global clinical development across the radiopharmaceutical portfolio, from early innovation to registrational strategy. Next up: smarter trials, better patient selection, true integration of diagnostics + therapeutics - and most importantly, proving outcomes that meaningfully improve patient benefit. I look forward to working with many of you again! #ProstateCancer #RLT #PSMA #UrologicOncology #ClinicalTrials @oncodaily

También el Dr. @nachoduranm ha estado presente en @APCCC_Lugano, participando en uno de los principales foros internacionales en #oncologíaGU Desde #GUARDConsortium impulsamos la conexión entre profesionales y el intercambio de conocimiento a nivel global. #Oncología #UroOncology @UroTeragLATAM @DrFelixGuerrero @dralvaropinto @drenriquegrande @fcounago @docjavip @BerUrologia @DrJaVallejo @Maroto5Pablo @RodriguezAntona @AnaPlatabello1